These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 24613126)

  • 1. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
    Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
    Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
    Oh DY; Lee KW; Lee KH; Sohn CH; Park YS; Zang DY; Ryoo HM; Song HS; Kim JS; Kang HJ; Kim BS; Bang YJ
    Invest New Drugs; 2012 Jun; 30(3):1164-74. PubMed ID: 21404106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
    Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
    Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
    Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
    Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
    Das P; Eng C; Rodriguez-Bigas MA; Chang GJ; Skibber JM; You YN; Maru DM; Munsell MF; Clemons MV; Kopetz SE; Garrett CR; Shureiqi I; Delclos ME; Krishnan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):301-5. PubMed ID: 24315563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
    Javle M; Yu J; Garrett C; Pande A; Kuvshinoff B; Litwin A; Phelan J; Gibbs J; Iyer R
    Br J Cancer; 2009 Jun; 100(12):1842-5. PubMed ID: 19491904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.